Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the safety of the combination (escalation
doses of NGR-hTNF, from 0.2 mcg/sqm to 1.6 mcg/sqm , with a fixed dose of cisplatin, 80
mg/sqm). Safety will be established by clinical and laboratory assessment according to
National Cancer Institute Common Toxicity Criteria (NCI-CTC ).